Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044659508> ?p ?o ?g. }
- W2044659508 endingPage "1140" @default.
- W2044659508 startingPage "1123" @default.
- W2044659508 abstract "Introduction: Commercially available cannabinoids are subject to psychotomimetic and addiction (cannabinomimetic) adverse effects largely through activation of the cannabinoid 1 receptor (CB1r). The available commercial cannabinoids have a narrow therapeutic index. Recently developed peripherally restricted cannabinoids, regionally administered cannabinoids, bifunctional cannabinoid ligands and cannabinoid enzyme inhibitors, endocannabinoids, which do not interact with classic cannabinoid receptors (CB1r and CB2r), cannabinoid receptor antagonists and selective CB1r agonists hold promise as analgesics.Areas covered: This author provides a review of the current investigational cannabinoids currently in development for pain management. The author also provides their perspective on the future of the field.Expert opinion: Regional and peripherally restricted cannabinoids will reduce cannabinomimetic side effects. Spinal cannabinoids may increase the therapeutic index by limiting the dose necessary for response and minimize drugs exposure to supraspinal sites where cannabinomimetic side effects originate. Cannabinoid bifunctional ligands should be further explored. The combination of a CB2r agonist with a transient receptor potential vanilloid (TRPV-1) antagonist may improve the therapeutic index of the CB2r agonist. Enzyme inhibitors plus TRPV-1 blockers should be further explored. The development of analgesic tolerance with enzyme inhibitors and the pronociceptive effects of prostamides limit the benefits to cannabinoid hydrolyzing enzyme inhibitors. Most clinically productive development of cannabinoids over the next 5 years will be in the area of selective CB2r agonists. These agents will be tested in various inflammatory, osteoarthritis and neuropathic pains." @default.
- W2044659508 created "2016-06-24" @default.
- W2044659508 creator A5017540677 @default.
- W2044659508 date "2014-05-16" @default.
- W2044659508 modified "2023-10-06" @default.
- W2044659508 title "Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands" @default.
- W2044659508 cites W1489971125 @default.
- W2044659508 cites W1491261527 @default.
- W2044659508 cites W1492563575 @default.
- W2044659508 cites W1500005891 @default.
- W2044659508 cites W1521779445 @default.
- W2044659508 cites W1542530495 @default.
- W2044659508 cites W1550617675 @default.
- W2044659508 cites W1553366132 @default.
- W2044659508 cites W1554897154 @default.
- W2044659508 cites W1557215935 @default.
- W2044659508 cites W1565584672 @default.
- W2044659508 cites W1566727921 @default.
- W2044659508 cites W1568755291 @default.
- W2044659508 cites W1578820780 @default.
- W2044659508 cites W1586162370 @default.
- W2044659508 cites W1593785499 @default.
- W2044659508 cites W1597172713 @default.
- W2044659508 cites W1597609644 @default.
- W2044659508 cites W1616061190 @default.
- W2044659508 cites W1654380405 @default.
- W2044659508 cites W1685180105 @default.
- W2044659508 cites W1744763481 @default.
- W2044659508 cites W1819429514 @default.
- W2044659508 cites W1876729781 @default.
- W2044659508 cites W1918174127 @default.
- W2044659508 cites W1943422062 @default.
- W2044659508 cites W1963753398 @default.
- W2044659508 cites W1967248406 @default.
- W2044659508 cites W1967303451 @default.
- W2044659508 cites W1967922769 @default.
- W2044659508 cites W1968917850 @default.
- W2044659508 cites W1970618996 @default.
- W2044659508 cites W1970888392 @default.
- W2044659508 cites W1973788448 @default.
- W2044659508 cites W1974249296 @default.
- W2044659508 cites W1974781686 @default.
- W2044659508 cites W1975298736 @default.
- W2044659508 cites W1977183929 @default.
- W2044659508 cites W1978984215 @default.
- W2044659508 cites W1980502203 @default.
- W2044659508 cites W1980612820 @default.
- W2044659508 cites W1980972832 @default.
- W2044659508 cites W1982029344 @default.
- W2044659508 cites W1982429227 @default.
- W2044659508 cites W1987729666 @default.
- W2044659508 cites W1988952674 @default.
- W2044659508 cites W1989155012 @default.
- W2044659508 cites W1989289560 @default.
- W2044659508 cites W1989814102 @default.
- W2044659508 cites W1991001962 @default.
- W2044659508 cites W1993908600 @default.
- W2044659508 cites W1994410805 @default.
- W2044659508 cites W1996348712 @default.
- W2044659508 cites W1996712837 @default.
- W2044659508 cites W1997568788 @default.
- W2044659508 cites W1998165103 @default.
- W2044659508 cites W1998867959 @default.
- W2044659508 cites W1999646805 @default.
- W2044659508 cites W2000030224 @default.
- W2044659508 cites W2004468399 @default.
- W2044659508 cites W2006242135 @default.
- W2044659508 cites W2006503897 @default.
- W2044659508 cites W2007485514 @default.
- W2044659508 cites W2007918392 @default.
- W2044659508 cites W2008426814 @default.
- W2044659508 cites W2008749179 @default.
- W2044659508 cites W2013156016 @default.
- W2044659508 cites W2013460111 @default.
- W2044659508 cites W2014493412 @default.
- W2044659508 cites W2015263236 @default.
- W2044659508 cites W2017099668 @default.
- W2044659508 cites W2017441297 @default.
- W2044659508 cites W2017652230 @default.
- W2044659508 cites W2018655546 @default.
- W2044659508 cites W2020010905 @default.
- W2044659508 cites W2020825180 @default.
- W2044659508 cites W2022288237 @default.
- W2044659508 cites W2022636007 @default.
- W2044659508 cites W2023478532 @default.
- W2044659508 cites W2023491486 @default.
- W2044659508 cites W2025755800 @default.
- W2044659508 cites W2026387596 @default.
- W2044659508 cites W2026671892 @default.
- W2044659508 cites W2027246433 @default.
- W2044659508 cites W2030135878 @default.
- W2044659508 cites W2032888644 @default.
- W2044659508 cites W2033857750 @default.
- W2044659508 cites W2034078410 @default.
- W2044659508 cites W2034433367 @default.
- W2044659508 cites W2035963270 @default.
- W2044659508 cites W2039644514 @default.
- W2044659508 cites W2040214635 @default.